Steven Cohen Oncorus, Inc. Transaction History

Point72 Asset Management, L.P.

  • $36.6 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021
SELL
$11.89 - $35.55 $546,583 - $1.63 Million
-45,970 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$15.0 - $35.15 $689,550 - $1.62 Million
45,970 New
45,970 $1.49 Million

About Oncorus, Inc.

ONCR Quotes by TradingView
  • Ticker ONCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,973,100
  • Description
  • Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...
More about ONCR
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email